56 related articles for article (PubMed ID: 16025585)
1. Lysophosphatidic acid: friend or foe of the ovarian surface epithelium.
Park DJ; Martyn KD; Warn-Cramer BJ
Hawaii Med J; 2005 Jun; 64(6):164-5, 169. PubMed ID: 16025585
[No Abstract] [Full Text] [Related]
2. [Ca 125 in epithelial ovarian cancers of FIGO stage I].
Nagele F; Kurz C; Vavra N; Sevelda P
Gynakol Geburtshilfliche Rundsch; 1993; 33 Suppl 1():291-2. PubMed ID: 8118320
[No Abstract] [Full Text] [Related]
3. Hypoxia enhances lysophosphatidic acid responsiveness in ovarian cancer cells and lysophosphatidic acid induces ovarian tumor metastasis in vivo.
Kim KS; Sengupta S; Berk M; Kwak YG; Escobar PF; Belinson J; Mok SC; Xu Y
Cancer Res; 2006 Aug; 66(16):7983-90. PubMed ID: 16912173
[TBL] [Abstract][Full Text] [Related]
4. [Interdependent prognostic factors in ovarian cancer].
Pickel H; Lahousen M
Gynakol Geburtshilfliche Rundsch; 1993; 33 Suppl 1():199. PubMed ID: 8118268
[No Abstract] [Full Text] [Related]
5. Biologic prognostic factors in ovarian cancer: a review.
Framarino dei Malatesta ML; Veneziano M; Peppicelli M; Lanzi G; Marzetti L
Eur J Gynaecol Oncol; 1998; 19(2):123-5. PubMed ID: 9611049
[TBL] [Abstract][Full Text] [Related]
6. P16INK4a overexpression is associated with poor clinical outcome in ovarian carcinoma.
Raspollini MR; Amunni G; Villanucci A; Baroni G; Taddei GL
J Chemother; 2004 Aug; 16(4):411-3. PubMed ID: 15332720
[No Abstract] [Full Text] [Related]
7. The effect of cyclooxygenase-2 expression on tumor vascularity in advanced stage ovarian serous carcinoma.
Ali-Fehmi R; Che M; Khalifeh I; Malone JM; Morris R; Lawrence WD; Munkarah AR
Cancer; 2003 Oct; 98(7):1423-9. PubMed ID: 14508829
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors in ovarian cancer.
Tropé C
Cancer Treat Res; 1998; 95():287-352. PubMed ID: 9619290
[No Abstract] [Full Text] [Related]
9. Expressions of fatty acid synthase and HER2 are correlated with poor prognosis of ovarian cancer.
Cai Y; Wang J; Zhang L; Wu D; Yu D; Tian X; Liu J; Jiang X; Shen Y; Zhang L; Ren M; Huang P
Med Oncol; 2015 Jan; 32(1):391. PubMed ID: 25433947
[TBL] [Abstract][Full Text] [Related]
10. c-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma.
Tomić S; Ilić Forko J; Babić D; Sundov D; Kuret S; Andelinović S
Croat Med J; 2003 Aug; 44(4):429-34. PubMed ID: 12950146
[TBL] [Abstract][Full Text] [Related]
11. Early detection and prognosis of ovarian cancer using serum YKL-40.
Dupont J; Tanwar MK; Thaler HT; Fleisher M; Kauff N; Hensley ML; Sabbatini P; Anderson S; Aghajanian C; Holland EC; Spriggs DR
J Clin Oncol; 2004 Aug; 22(16):3330-9. PubMed ID: 15310777
[TBL] [Abstract][Full Text] [Related]
12. Four potential biomarkers as prognostic factors in stage III serous ovarian adenocarcinomas.
Partheen K; Levan K; Osterberg L; Claesson I; Fallenius G; Sundfeldt K; Horvath G
Int J Cancer; 2008 Nov; 123(9):2130-7. PubMed ID: 18709641
[TBL] [Abstract][Full Text] [Related]
13. Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma.
Diamandis EP; Scorilas A; Fracchioli S; Van Gramberen M; De Bruijn H; Henrik A; Soosaipillai A; Grass L; Yousef GM; Stenman UH; Massobrio M; Van Der Zee AG; Vergote I; Katsaros D
J Clin Oncol; 2003 Mar; 21(6):1035-43. PubMed ID: 12637468
[TBL] [Abstract][Full Text] [Related]
14. Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis.
Sherman ME; Mink PJ; Curtis R; Cote TR; Brooks S; Hartge P; Devesa S
Cancer; 2004 Mar; 100(5):1045-52. PubMed ID: 14983501
[TBL] [Abstract][Full Text] [Related]
15. [Clinical aspects in expression of epidermal growth factor receptors in epithelial ovarian tumors].
Tomov S; Gorchev G; Khinkova N; Tsingilev D
Akush Ginekol (Sofiia); 2007; 46(4):29-33. PubMed ID: 17974192
[No Abstract] [Full Text] [Related]
16. Ovarian cancer: histogenetic classification, histologic grading, diagnosis, staging, and epidemiology.
Jolles CJ
Clin Obstet Gynecol; 1985 Dec; 28(4):787-99. PubMed ID: 3000668
[TBL] [Abstract][Full Text] [Related]
17. Outcome of recurrent and persistent disease of malignant ovarian germ cell tumor: a retrospective analysis at King Chulalongkorn Memorial Hospital.
Lertkhachonsuk R; Manchana T; Termrungruanglert W; Vasuratna A; Sittisomwong T; Worasethsin P; Sirisabya N; Khemapech N; Tresukosol D
J Med Assoc Thai; 2006 Feb; 89(2):138-44. PubMed ID: 16578998
[TBL] [Abstract][Full Text] [Related]
18. The human lipid phosphate phosphatase-3 decreases the growth, survival, and tumorigenesis of ovarian cancer cells: validation of the lysophosphatidic acid signaling cascade as a target for therapy in ovarian cancer.
Tanyi JL; Morris AJ; Wolf JK; Fang X; Hasegawa Y; Lapushin R; Auersperg N; Sigal YJ; Newman RA; Felix EA; Atkinson EN; Mills GB
Cancer Res; 2003 Mar; 63(5):1073-82. PubMed ID: 12615725
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
[TBL] [Abstract][Full Text] [Related]
20. Constitutive and lysophosphatidic acid (LPA)-induced LPA production: role of phospholipase D and phospholipase A2.
Eder AM; Sasagawa T; Mao M; Aoki J; Mills GB
Clin Cancer Res; 2000 Jun; 6(6):2482-91. PubMed ID: 10873103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
